Healthcare Professionals
Explore the groundbreaking results of the SOLVE-CRT trial, a pivotal study stopped early for success at the pre-specified interim analysis. This trial demonstrated safety and effectiveness of the WiSE CRT System with conventional CRT who were previously untreatable or considered high risk upgrades.
EBR's pivotal SOLVE-CRT Study published in JAMA Cardiology
The SOLVE-CRT trial evaluated patients indicated for CRT who were previously untreatable or considered high risk upgrades. The study found that the WiSE System, the only leadless left ventricular endocardial pacing (LVEP) device, can safely deliver CRT.16.4% improvement in left ventricular end systolic volume (LVESV), in heart failure patients in the first 6-months.80.9% of patients had no serious procedure or device-related complications in the first 6-months.
Learn MoreNews
eIFU
From this site you can view Instructions for Use (IFUs) and Patient Information Booklets (PIB). Please note, Product Literature might vary by geography (region) and language. Use only literature from the region where the patient procedure was performed. Product Literature is subject to change; the most current version is available on this page.
The information should be carefully reviewed and followed when using any device. Failure to follow the instructions may result in unacceptable performance and increased risk of patient harm. If you do not find the desired documents for your region or would like to request a paper/emailed copy, please visit our Contact page.
Adobe Reader is required to view PDF files.
WiSE Clinical Program
Studies demonstrate on-going clinical impact of WiSE CRT System, the leadless left ventricular endocardial pacing (LVEP) solution.


